Cargando…

Clinicopathological Features and Prognostic Evaluation of UBR5 in Liver Cancer Patients

Background: Typically, liver cancer patients are diagnosed at an advanced stage and have a poor prognosis. N-recognin 5 (UBR5), a component of the ubiquitin protein ligase E3, is involved in the genesis and progression of several types of cancer. As of yet, it is unknown what the exact biological fu...

Descripción completa

Detalles Bibliográficos
Autores principales: Huo, Qi, Hu, Junjie, Hou, Binfen, Zhao, Mei, Han, Xue, Du, Yulin, Li, Yao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9665233/
https://www.ncbi.nlm.nih.gov/pubmed/36388433
http://dx.doi.org/10.3389/pore.2022.1610396
_version_ 1784831245749846016
author Huo, Qi
Hu, Junjie
Hou, Binfen
Zhao, Mei
Han, Xue
Du, Yulin
Li, Yao
author_facet Huo, Qi
Hu, Junjie
Hou, Binfen
Zhao, Mei
Han, Xue
Du, Yulin
Li, Yao
author_sort Huo, Qi
collection PubMed
description Background: Typically, liver cancer patients are diagnosed at an advanced stage and have a poor prognosis. N-recognin 5 (UBR5), a component of the ubiquitin protein ligase E3, is involved in the genesis and progression of several types of cancer. As of yet, it is unknown what the exact biological function of UBR5 is in liver cancer. Methods: A Kaplan-Meier survival curve (OS) was used to examine the effect of UBR5 expression on overall survival based on the TCGA database. To determine the molecular functions of UBR5 in liver cancer, we used the Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) databases. A protein-protein interaction (PPI) network was established for the screening of UBR5-related proteins in liver cancer. Western blot analysis was used to determine the expression levels of UBR5 and YWHAZ (tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta), and in order to detect cell proliferation, an MTT assay was used. Results: The expression of UBR5 in liver cancer patient samples is significantly higher than in adjacent normal tissues. A high level of UBR5 expression was associated with older patients, a higher tumor grade, lymph node metastasis, and poor survival. We discovered YWHAZ with high connectivity, and UBR5 expression correlated positively with YWHAZ expression (r = 0.83, p < 0.05). Furthermore, we found that elevated UBR5 levels directly correlated with YWHAZ overexpression, and that UBR5 promoted cell proliferation by affecting YWHAZ expression. Additionally, the TCGA databases confirmed that patients with liver cancer who expressed higher levels of YWHAZ had poorer outcomes. Conclusion: This suggests that UBR5 associated with YWHAZ may influence prognosis in patients with liver cancer, and that UBR5 may be a candidate treatment target for liver cancer. Therefore, UBR5 associated with YWHAZ may influence prognosis in patients with liver cancer, and UBR5 could serve as a potential target for liver cancer treatment.
format Online
Article
Text
id pubmed-9665233
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-96652332022-11-15 Clinicopathological Features and Prognostic Evaluation of UBR5 in Liver Cancer Patients Huo, Qi Hu, Junjie Hou, Binfen Zhao, Mei Han, Xue Du, Yulin Li, Yao Pathol Oncol Res Pathology and Oncology Archive Background: Typically, liver cancer patients are diagnosed at an advanced stage and have a poor prognosis. N-recognin 5 (UBR5), a component of the ubiquitin protein ligase E3, is involved in the genesis and progression of several types of cancer. As of yet, it is unknown what the exact biological function of UBR5 is in liver cancer. Methods: A Kaplan-Meier survival curve (OS) was used to examine the effect of UBR5 expression on overall survival based on the TCGA database. To determine the molecular functions of UBR5 in liver cancer, we used the Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) databases. A protein-protein interaction (PPI) network was established for the screening of UBR5-related proteins in liver cancer. Western blot analysis was used to determine the expression levels of UBR5 and YWHAZ (tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta), and in order to detect cell proliferation, an MTT assay was used. Results: The expression of UBR5 in liver cancer patient samples is significantly higher than in adjacent normal tissues. A high level of UBR5 expression was associated with older patients, a higher tumor grade, lymph node metastasis, and poor survival. We discovered YWHAZ with high connectivity, and UBR5 expression correlated positively with YWHAZ expression (r = 0.83, p < 0.05). Furthermore, we found that elevated UBR5 levels directly correlated with YWHAZ overexpression, and that UBR5 promoted cell proliferation by affecting YWHAZ expression. Additionally, the TCGA databases confirmed that patients with liver cancer who expressed higher levels of YWHAZ had poorer outcomes. Conclusion: This suggests that UBR5 associated with YWHAZ may influence prognosis in patients with liver cancer, and that UBR5 may be a candidate treatment target for liver cancer. Therefore, UBR5 associated with YWHAZ may influence prognosis in patients with liver cancer, and UBR5 could serve as a potential target for liver cancer treatment. Frontiers Media S.A. 2022-11-01 /pmc/articles/PMC9665233/ /pubmed/36388433 http://dx.doi.org/10.3389/pore.2022.1610396 Text en Copyright © 2022 Huo, Hu, Hou, Zhao, Han, Du and Li. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pathology and Oncology Archive
Huo, Qi
Hu, Junjie
Hou, Binfen
Zhao, Mei
Han, Xue
Du, Yulin
Li, Yao
Clinicopathological Features and Prognostic Evaluation of UBR5 in Liver Cancer Patients
title Clinicopathological Features and Prognostic Evaluation of UBR5 in Liver Cancer Patients
title_full Clinicopathological Features and Prognostic Evaluation of UBR5 in Liver Cancer Patients
title_fullStr Clinicopathological Features and Prognostic Evaluation of UBR5 in Liver Cancer Patients
title_full_unstemmed Clinicopathological Features and Prognostic Evaluation of UBR5 in Liver Cancer Patients
title_short Clinicopathological Features and Prognostic Evaluation of UBR5 in Liver Cancer Patients
title_sort clinicopathological features and prognostic evaluation of ubr5 in liver cancer patients
topic Pathology and Oncology Archive
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9665233/
https://www.ncbi.nlm.nih.gov/pubmed/36388433
http://dx.doi.org/10.3389/pore.2022.1610396
work_keys_str_mv AT huoqi clinicopathologicalfeaturesandprognosticevaluationofubr5inlivercancerpatients
AT hujunjie clinicopathologicalfeaturesandprognosticevaluationofubr5inlivercancerpatients
AT houbinfen clinicopathologicalfeaturesandprognosticevaluationofubr5inlivercancerpatients
AT zhaomei clinicopathologicalfeaturesandprognosticevaluationofubr5inlivercancerpatients
AT hanxue clinicopathologicalfeaturesandprognosticevaluationofubr5inlivercancerpatients
AT duyulin clinicopathologicalfeaturesandprognosticevaluationofubr5inlivercancerpatients
AT liyao clinicopathologicalfeaturesandprognosticevaluationofubr5inlivercancerpatients